Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Renal Impact: Rivaroxaban Versus Vitamin K Antagonists in AF
Author(s): Phong Phan Dinh , Tri Huynh Quang Ho , Hung Manh Pham , et al Added: 11 months ago

Anticoagulation

Electrophysiology & Arrhythmia
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 1 year ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
Selecting NOAC to Optimise Stroke Prevention in AF – Part 1
Author(s): Tri Huynh Quang Ho , Minh That Ton , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
Selecting NOAC to Optimise Stroke Prevention in AF – Part 2
Author(s): Minh That Ton , Tri Huynh Quang Ho , Viet Lan Nguyen , et al Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
EHRA 24: A Substudy of NOAH-AFNET 6
Author(s): Julius Nikorowitsch Added: 1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more

Electrophysiology & Arrhythmia
HFA 24: FINE-HEART: Design & Baseline Characteristics
Author(s): Muthiah Vaduganathan Added: 12 months ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more

Heart Failure

Prevention & Chronic Conditions
ESC 24: MRAs in Heart Failure
Author(s): Added: 8 months ago
ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF.Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.This pre-specified, patient-level meta-analysis of RALES (spironolactone), EMPHASIS-HF (eplerenone), TOPCAT… View more

Heart Failure
ESC 24: FINE-HEART: Finerenone in HF & CKD
Author(s): Muthiah Vaduganathan Added: 8 months ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical… View more

Heart Failure

Prevention & Chronic Conditions
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 1 month ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 1 year ago
ESC 2023 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF trial (NCT04788511). Around half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and most patients with HFpEF are overweight or obese. Patients with… View more

Heart Failure

Prevention & Chronic Conditions